Ingredients in every ml
Each package contains
|ATC Level 1||M - Musculo-skeletal system|
|ATC Level 2||M01 - Antiinflammatory and Antirheumatic Products|
|ATC Level 3||M01A - Antiinflammatory and Antirheumatic Products; Non-Steroids|
16 TO 65 YEARS OLD
— Single dose IM: 1x60 mg
— Single dose IV: 1x30 mg
— Repeated IM or IV: 30 mg every 6 hours, maximum 120 mg daily
65 YEARS OLD AND ABOVE
— Single dose IM: 1x30 mg
— Single dose IV: 1x15 mg
— Repeated IM or IV: 15 mg every 6 hours, maximum 60 mg daily
0 TO 16 YEARS OLD
Ketorolac trometamol is not recommended (safety and efficacy have not been established).
Long-term treatment of ketorolac IV and IM should not exceed 5 days. Hypovolemia should be corrected prior to the administration of ketorolac trometamol. The IV bolus must be given over no less than 15 seconds. The IM administration should be given deeply and slowly into the muscle. The analgesic effect begins in 30 minutes with maximum effect occurring in 1-2 hours after dosing IV or IM. The duration of analgesic effect is usually 4-6 hours. For breakthrough pain, do not increase the dose or the frequency of ketorolac trometamol. Consideration should be given to supplementing these regiments with low doses of opioids unless otherwise contraindicated.
PATIENTS WITH HEPATIC IMPAIRMENT
Ketorolac should be used with caution in patients with impaired hepatic function or a history of liver disease. Administration of ketorolac should be discontinued if abnormality of hepatic function test occurs after ketorolac administration.
Ketorolac is indicated for the short-term (≤5 days) management of severe acute pain that requires analgesia at the opioid level.